Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing...

Source: The Rheumatologist - October 1, 2020 Category: Rheumatology Authors: Ruth Jessen Hickman, MD Tags: Drug Updates Osteoarthritis Arthritis & Rheumatology fasinumab Knee Osteoarthritis (OA) Nerve growth factor (NGF) tanezumab Source Type: research